Key facts
- This page summarizes Sekar Kathiresan's Form 3 filing for Maze Therapeutics, Inc. (MAZE).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2025, 16:33.
Sekar Kathiresan - 30 Jan 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)
- Reporting relationship
- Director
- Issuer ticker
- MAZE
- Reported as of
- 30 Jan 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 30 Jan 2025, 16:33:09 UTC
- Prior SEC filing
- 10 Jan 2025
- Next SEC filing
- 03 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Courtney Phillips, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sekar Kathiresan filed Form 3 for Maze Therapeutics, Inc. (MAZE) on 30 Jan 2025.
Change
- Previous filing in this sequence was filed on 10 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MAZE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 103,723
- Date
- 30 Jan 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MAZE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,744
- Exercise price
- $10.42
- Footnotes
- F1
MAZE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,086
- Exercise price
- $10.42
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on May 21, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F2
The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.